Freeline Therapeutics Holdings PLC
https://www.freeline.life/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Freeline Therapeutics Holdings PLC
€80m Cash Boost Helps iOnctura Accelerate Eye Cancer Candidate
The proceeds from the impressive series B financing will help progress roginolisib through Phase II trials.
Two Better Than One As Syncona Creates Spur
The merger of Freeline and SwanBio is establishing an entity with secure financing to advance their respective gene therapies for Gaucher’s disease and adrenomyeloneuropathy.
Freeline, Wugen & Jnana Secure EMA PRIME Designations For Novel Treatments
A one-time gene therapy candidate for Gaucher disease, an allogeneic CAR-T cell therapy for difficult-to-treat blood cancers, and a potentially first-in-class drug for treating hyperphenylalaninemia have made it onto the European Medicines Agency’s priority medicines scheme.
Syncona Buys Out Ailing Gene Therapy Company Freeline
Syncona has stepped in to save Freeline and give it more time to prove the value of FLT201, its early-stage Gaucher’s disease gene therapy.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice